Affluent Medical SA (AFME) AI Stock Analysis

• Market Cap: €73.14M
• Dividend Yield: N/A
• Average Volume (3M): 9.49K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.42
• Revenue Growth: N/A
• EPS Growth: 30.04%
• Country: FR
• Employees: 66
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.24
• Shares Outstanding: 39,348,312
• 10 Day Avg. Volume: 9,769
• 30 Day Avg. Volume: 9,492
• PEG Ratio: 0.11
• Price to Book (P/B): 1.75
• Price to Sales (P/S): 12.90
• P/FCF Ratio: -4.63
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €3.80
• Price Target Upside: 104.30% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: €1.50 ▼(-19.35% Downside)

Affluent Medical SA's overall stock score is primarily impacted by its financial performance challenges, including significant profitability and cash flow issues. While technical analysis shows positive price trends, the stock appears overbought, which could limit further upside. The valuation is also concerning due to the negative P/E ratio and lack of dividend yield.

Positive Factors

Revenue Growth

The substantial revenue growth indicates strong market demand for the company's products, suggesting potential for continued expansion and market penetration.

Cash Flow Improvement

Improved cash flow generation enhances financial flexibility, enabling the company to invest in growth opportunities and manage obligations more effectively.

Moderate Debt Levels

Moderate leverage indicates a balanced capital structure, allowing the company to potentially leverage debt for growth without excessive financial risk.

Negative Factors

Profitability Challenges

Persistent profitability issues highlight operational inefficiencies, which could hinder long-term financial sustainability and shareholder value creation.

Negative Return on Equity

Negative return on equity indicates the company is not effectively using shareholder funds to generate profits, which could impact investor confidence and capital raising ability.

Cash Flow Conversion Issues

Inability to convert earnings into cash effectively suggests operational inefficiencies, potentially affecting liquidity and investment capacity.

Affluent Medical SA Business Overview & Revenue Model

Company Description

Affluent Medical SA develops minimally invasive medical devices for the treatment of heart and vascular diseases in France. It develops Kardiozis technology for the treatment of abdominal aortic aneurysm; Kalios and Epygon implants to treat mitral insufficiency; and Artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. The company was founded in 2011 and is based in Aix-en-Provence, France.

How the Company Makes Money

Affluent Medical generates revenue through multiple streams, primarily by selling its medical devices and technologies to hospitals and healthcare providers. The company often engages in direct sales as well as distribution agreements with medical supply companies. Additionally, AFME may earn revenue from licensing its technologies to other medical device manufacturers or partnering with research institutions for collaborative development projects. Strategic partnerships with healthcare organizations and participation in clinical trials also contribute to its earnings by potentially increasing product visibility and market adoption.

Affluent Medical SA Financial Statement Overview

Summary

Affluent Medical SA exhibits strong revenue growth but faces significant profitability and cash flow challenges. The company maintains a moderate debt level, but negative returns on equity and cash flow inefficiencies highlight ongoing financial struggles. While there are signs of improvement in cash flow, the company needs to address its operational inefficiencies to achieve sustainable profitability.

Income Statement

Affluent Medical SA has shown significant revenue growth of 217.99% in the latest year, indicating strong top-line expansion. However, the company struggles with profitability, as evidenced by negative gross profit and net profit margins of -58.18% and -357.92%, respectively. The EBIT and EBITDA margins are also deeply negative, highlighting ongoing operational challenges.

Balance Sheet

The company's debt-to-equity ratio of 0.54 suggests moderate leverage, which is relatively stable compared to previous years. However, the return on equity is negative at -48.69%, indicating that the company is not generating positive returns for shareholders. The equity ratio stands at 49.75%, reflecting a balanced capital structure but with ongoing profitability issues.

Cash Flow

Affluent Medical SA's free cash flow has grown by 52.89%, showing improvement in cash generation. However, the operating cash flow to net income ratio is negative, indicating that the company is not converting its earnings into cash effectively. The free cash flow to net income ratio is slightly positive at 1.01, suggesting some level of cash flow stability despite overall financial challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.70M	4.12M	1.22M	1.34M	1.45M	824.00K
Gross Profit	-4.45M	-9.27M	-1.20M	-1.10M	-1.29M	-2.44M
EBITDA	-13.28M	-13.44M	-13.34M	-13.21M	-10.89M	-10.47M
Net Income	-14.74M	-14.74M	-15.65M	-15.23M	-14.82M	-14.32M
Balance Sheet
Total Assets	59.84M	60.86M	56.62M	60.02M	70.03M	64.83M
Cash, Cash Equivalents and Short-Term Investments	5.35M	6.62M	1.66M	2.58M	11.41M	5.65M
Total Debt	23.42M	16.33M	17.13M	17.73M	19.75M	20.78M
Total Liabilities	38.73M	30.59M	25.15M	26.19M	26.50M	29.54M
Stockholders Equity	21.11M	30.27M	31.47M	33.83M	43.53M	35.29M
Cash Flow
Free Cash Flow	-14.40M	-11.47M	-12.24M	-11.23M	-12.70M	-9.24M
Operating Cash Flow	-14.36M	-11.32M	-12.05M	-11.08M	-12.36M	-8.94M
Investing Cash Flow	4.80M	-480.00K	-184.00K	-146.00K	-160.00K	-304.00K
Financing Cash Flow	13.98M	11.37M	11.32M	2.40M	18.28M	12.76M

Affluent Medical SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:AFME, the sentiment is Positive. The current price of 1.86 is above the 20-day moving average (MA) of 1.67, above the 50-day MA of 1.60, and above the 200-day MA of 1.46, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 60.80 is Neutral, neither overbought nor oversold. The STOCH value of 63.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:AFME.

Affluent Medical SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AFME	48 Neutral	€73.14M	-4.96	-62.69%	―	―	30.04%
ALMDT	47 Neutral	€153.54M	-3.59	―	―	6.75%	15.48%
ALTHE	45 Neutral	€35.47M	-4.77	-2351.12%	―	-4.70%	-64.31%
ALCAR	40 Underperform	€6.35M	-0.08	―	―	―	―